For people with type 1 diabetes
INNODIA brings together diabetes experts from across Europe and is conducting a study in type1 diabetes to discover new factors to predict the risk of developing the disease, and new treatments and ways of preserving insulin production. Getting a more complete view on different ‘biomarkers’, ie factors in your blood, urine or stool, that can predict the development and evolution of type 1 diabetes, is crucial for a better and earlier diagnosis for people at risk to developing the disease as well as for a better follow-up and eventually finding a cure for the patients.
Such biomarkers can by identified by analyzing your blood, urine and stool samples.
In the first phase of the project, INNODIA recruited children and adults across Europe aged between 1 and 45 years who had been diagnosed with type 1 diabetes within the previous 6 weeks, called an observational study.
Recruitment target has now been reached!
Thank you to all people with type 1 diabetes who already had their final INNODIA visit and those who are still participating in this project! Your contribution is crucial for type 1 diabetes research.
In the next phase; the collected samples and data will be examined in great detail.
Clinical trials
People with newly diagnosed type 1 diabetes (maximum 6 weeks after diagnosis) can now take part in research that aims to generate knowledge helping to arrest further disease development.
The aim of these studies is to halt the further decline in beta cell functionality in people with newly diagnosed T1D, addressing the immune system or the beta cells by different treatment modalities.
Read more
How can I participate to INNODIA?
Listen to DELTA!Research related publications
The late Prof. David Dunger - University of Cambridge
Olivier Arnaud - JDRF